{"nctId":"NCT03151993","briefTitle":"Single Bolus Recombinant Nonimmunogenic Staphylokinase (Fortelyzin) and Bolus Infusion Alteplase in Patients With AIS","startDateStruct":{"date":"2017-03-18","type":"ACTUAL"},"conditions":["Ischemic Stroke"],"count":336,"armGroups":[{"label":"Recombinant staphylokinase","type":"EXPERIMENTAL","interventionNames":["Drug: Recombinant staphylokinase"]},{"label":"Actilyse","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Alteplase"]}],"interventions":[{"name":"Recombinant staphylokinase","otherNames":["Fortelyzin"]},{"name":"Alteplase","otherNames":["Actilyse"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Men and women between the ages of 18 and 80 (Version 1.0)\n* Men and women aged 18 years and older, after 80 years with caution (Version 2.0)\n* Verified diagnosis of ischemic stroke (from 5 to 25 points on the NIHSS scale). (Version 1.0)\n* Verified diagnosis of ischemic stroke (Version 2.0)\n* The time from the onset of the disease is no more than 4.5 hours.\n* Informed consent received\n\nExclusion Criteria:\n\n* The time of the onset of the first symptoms is more than 4.5 hours from the onset of the disease or the time of the onset of the first symptoms of a stroke is not known (for example, the development of a stroke during sleep - the so-called \"night stroke\").\n* Increased sensitivity to alteplase, gentamicin (residual traces from the production process).\n* Systolic blood pressure above 185 mm Hg. Art. Or diastolic blood pressure above 110 mm Hg. Art. Or the need for / in the administration of drugs to reduce blood pressure to these boundaries.\n* Neuroimaging (CT, MRI) signs of intracranial hemorrhage, brain tumors, arteriovenous malformation, brain abscess, aneurysm of cerebral vessels.\n* Surgery on the brain or spinal cord.\n* Suspicion of subarachnoid hemorrhage.\n* Signs of severe stroke: clinical signs (stroke scale NIH\\> 25), neuroimaging (according to CT of the brain and / or MRI of the brain in the DWI, the ischemia focuses on the territory of more than 1/3 of the CMA pool).\n* Simultaneous reception of oral anticoagulants, for example, warfarin with INR\\> 1.3.\n* The use of direct anticoagulants (heparin, heparinoids) in the preceding stroke of 48 h with APTT values above the norm.\n* Prior stroke or severe head injury within 3 months.\n* Significant regression of neurological symptoms during the observation of the patient.(Version 1.0)\n* Light neurological symptoms (NIH \\<4 points). (Version 1.0)\n* Significant regression of neurological symptoms during the observation of the patient before thrombolisis (Version 2.0)\n* Hemorrhagic stroke or stroke, unspecified in history.\n* Strokes of any genesis in the history of a patient with diabetes mellitus.\n* Gastrointestinal bleeding or bleeding from the genitourinary system in the last 3 weeks. Confirmed exacerbations of gastric ulcer and duodenal ulcer during the last 3 months.\n* Extensive bleeding now or within the previous 6 months.\n* Severe liver disease, including liver failure, cirrhosis, portal hypertension (with varicose veins of the esophagus), active hepatitis.\n* Acute pancreatitis.\n* Bacterial endocarditis, pericarditis.\n* Aneurysms of arteries, malformations of arteries and veins. Suspicion of exfoliating aortic aneurysm.\n* Neoplasms with an increased risk of bleeding.\n* Large operations or severe injuries within the last 14 days, minor surgery or invasive manipulation in the last 10 days.\n* Puncture of uncompensated arteries and veins during the last 7 days.\n* Prolonged or traumatic cardiopulmonary resuscitation (more than 2 min).\n* Pregnancy, obstetrics, 10 days after birth.\n* The number of platelets is less than 100,000 / Î¼L.\n* Blood glucose less than 2.7 mmol / l or more than 22.0 mmol / l.\n* Hemorrhagic diathesis, including renal and hepatic insufficiency.\n* Data on bleeding or acute trauma (fracture) at the time of examination.\n* Seizures in the onset of the disease, if there is no certainty that the seizure is a clinical manifestation of ischemic stroke with a postictal residual deficiency.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Good Functional Recovery","description":"The number of patients with Modified Rankin Scale (mRS) scores 0-1 on day 90 after drug administration, where 0 - No symptoms, 1 - No significant disability. All scale is 0 - No symptoms, 1 - No significant disability, 2 - Slight disability, 3 - Moderate disability, 4 - Moderately severe disability, 5 - Severe disability, 6 - Dead.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"84","spread":null},{"groupId":"OG001","value":"68","spread":null}]}]}]},{"type":"SECONDARY","title":"The Number of Patients With Modified Rankin Scale (0-1) + NIHSS (0-1) + Barthel (95-100)","description":"Composite endpoint, included the number of patients reached Modified Rankin scale 0-1 score, NIHSS 0-1 score and Barthel index 95-100.\n\nModified Rankin scale: 0 - No symptoms, 1 - No significant disability, 2 - Slight disability, 3 - Moderate disability, 4 - Moderately severe disability, 5 - Severe disability, 6 - Dead.\n\nThe National Institutes of Health Stroke Scale (NIHSS): 0 - No stroke symptoms, 1-4 - Minor stroke, 5-15 - Moderate stroke, 16-20 - Moderate to severe stroke, 21-42 - Severe stroke.\n\nBarthel index: 80-100 - Independent, 60-79 - Minimally dependent, 40-59 - Partially dependent, 20-39 - Very dependent, \\<20 - Totally dependent.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"59","spread":null},{"groupId":"OG001","value":"52","spread":null}]}]}]},{"type":"SECONDARY","title":"The Median of NIHSS After 24 Hours","description":"The median of The National Institutes of Health Stroke Scale (NIHSS) at 24 h after drug administration, where: 0 - No stroke symptoms, 1-4 - Minor stroke, 5-15 - Moderate stroke, 16-20 - Moderate to severe stroke, 21-42 - Severe stroke.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]}]},{"type":"SECONDARY","title":"The Median of NIHSS After 90 Days","description":"The median of The National Institutes of Health Stroke Scale (NIHSS) after 90 days of drug administration, where: 0 - No stroke symptoms, 1-4 - Minor stroke, 5-15 - Moderate stroke, 16-20 - Moderate to severe stroke, 21-42 - Severe stroke.","paramType":"MEDIAN","dispersionType":"Inter-Quartile Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"All Cause Death","description":"Death caused by any event","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null},{"groupId":"OG001","value":"24","spread":null}]}]}]},{"type":"SECONDARY","title":"Intracranial Haemorrhage","description":"The number of intracranial hemorrhage (events)","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":null},{"groupId":"OG001","value":"28","spread":null}]}]}]},{"type":"SECONDARY","title":"Symptomatic Intracranial Haemorrhage","description":"The number of symptomatic intracranial haemorrhage according to ECASS III definition (events). The ECASS III definition of symptomatic intracranial haemorrhage was any haemorrhage with neurologic deterioration, as indicated by an NIHSS score that was higher by 4 points or more than the value at baseline or the lowest value in the first 7 days, or any haemorrhage leading to death. In addition, the haemorrhage must have been identified as the predominant cause of the neurologic deterioration.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":22,"n":168},"commonTop":["Haematuria"]}}}